

Table SI. Standardized annual prevalence of PsA among patients with PsO from 2008 to 2020

Calendar years	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Standardized annual prevalence													
Standardized prevalence per 1,000 patients (95% CI)	6.17 (5.73-6.65)	5.45 (5.03-5.90)	5.64 (5.22-6.10)	5.92 (5.48-6.38)	6.65 (6.19-7.15)	6.89 (6.42-7.39)	8.30 (7.79-8.85)	9.16 (8.61-9.73)	9.91 (9.34-10.51)	11.51 (10.90-12.15)	13.89 (13.22-14.60)	16.57 (15.84-17.34)	18.98 (18.19-19.80)
No. of standard PsO population ¹	112,023	112,023	112,023	112,023	112,023	112,023	112,023	112,023	112,023	112,023	112,023	112,023	112,023
No. of expected patients with PsA	691	610	632	663	745	772	930	1,026	1,110	1,289	1,556	1,856	2,126

¹ Used mid-year PsO population in 2008
CI, confidence interval.

Table SII. Crude and standardized annual incidence ratio of PsA among patients with PsO from 2008 to 2020

	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Crude annual incidence													
Crude incidence per 1,000 patients	3.13	2.51	2.68	2.81	2.86	2.97	3.57	3.37	3.32	4.11	4.71	4.98	4.99
95% CI	(2.82-3.48)	(2.25-2.80)	(2.42-2.97)	(2.55-3.10)	(2.60-3.14)	(2.71-3.25)	(3.29-3.87)	(3.10-3.66)	(3.06-3.61)	(3.81-4.42)	(4.39-5.05)	(4.66-5.33)	(4.66-5.34)
Number of mid-year PsO population ¹	111,470	129,394	137,684	143,929	149,381	155,498	160,070	163,653	166,510	168,734	167,809	169,928	164,780
Number of patients with PsA ²	349	325	369	405	427	462	571	551	553	693	790	847	822
Standardized annual incidence													
Standardized incidence per 1,000 patients	3.13	2.51	2.67	2.81	2.85	2.97	3.54	3.35	3.33	4.13	4.73	4.97	4.97
95% CI	(2.82-3.48)	(2.23-2.82)	(2.38-2.99)	(2.52-3.14)	(2.55-3.18)	(2.67-3.31)	(3.21-3.91)	(3.02-3.70)	(3.01-3.69)	(3.77-4.53)	(4.34-5.15)	(4.58-5.40)	(4.58-5.41)
Number of standard PsO population ³	111,470	111,470	111,470	111,470	111,470	111,470	111,470	111,470	111,470	111,470	111,470	111,470	111,470
Number of expected patients with PsA	349	279	298	313	318	331	394	373	371	461	527	554	555

¹ Defined as patients who had at least 1 prescription with any diagnosis of PsO before July 1st of the year of interest without PsA history

² Defined as patients who had at least 1 prescription with newly diagnosed PsA and had at least 1 prescription with any diagnosis of PsO before December 31st of the year of interest.

³ Used mid-year PsO population in 2008

CI, confidence interval; PsO, psoriasis; PsA, psoriatic arthritis

Table SIII. Distribution of matching variables before and after matching

Table S11. Distribution of matching variables before and after matching														
Variables	Before risk-set matching							After risk-set matching						
	All (N=856,583)		Case (N=6,427)		Control (N=850,156)		p-value	All (N=32,095)		Case (N=6,419)		Control (N=25,676)		p-value
	n	%	n	%	n	%		n	%	n	%	n	%	
Age as of PsO index date, yr														
18-19	20,665	2.41	116	1.80	20,549	2.42	<0.0001	580	1.81	116	1.81	464	1.81	1.0000
20-29	133,442	15.58	857	13.33	132,585	15.60		4,285	13.35	857	13.35	3,428	13.35	
30-39	164,146	19.16	1,284	19.98	162,862	19.16		6,420	20.00	1,284	20.00	5,136	20.00	
40-49	166,754	19.47	1,440	22.41	165,314	19.45		7,200	22.43	1,440	22.43	5,760	22.43	
50-59	164,042	19.15	1,370	21.32	162,672	19.13		6,850	21.34	1,370	21.34	5,480	21.34	
60-69	110,961	12.95	794	12.35	110,167	12.96		3,970	12.37	794	12.37	3,176	12.37	
70-79	72,155	8.42	476	7.41	71,679	8.43		2,380	7.42	476	7.42	1,904	7.42	
≥80	24,418	2.85	90	1.40	24,328	2.86		410	1.28	82	1.28	328	1.28	
Sex														
Male	468,447	54.69	3,523	54.82	464,924	54.69	0.8364	17,585	54.79	3,517	54.79	14,068	54.79	1.0000
Female	388,136	45.31	2,904	45.18	385,232	45.31		14,510	45.21	2,902	45.21	11,608	45.21	
Time to PsA index date, yr														
Mean	NA		3.82		NA		NA	3.82		3.82		3.82		0.9655
SD	NA		3.29		NA			3.29		3.29		3.29		
Median	NA		3.07		NA			3.06		3.07		3.06		
Min	NA		0.00		NA			0.00		0.00		0.00		
Max	NA		12.89		NA			12.95		12.89		12.95		
P25	NA		0.88		NA			0.90		0.89		0.90		
P75	NA		6.16		NA			6.16		6.17		6.16		